Major Pharmaceuticals
12 federal recalls on file. We monitor every CPSC, FDA, USDA, and NHTSA notice for Major Pharmaceuticals and translate it into plain English — free weekly digest, optional same-day alerts.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals levothyroxine tablets recalled for subpotency
Major Pharmaceuticals is recalling specific lots of levothyroxine sodium 150 mcg tablets because they contain less active ingredient than labeled. Levothyroxine is a thyroid hormone replacement medication, and subpotent tablets may not provide the intended therapeutic dose. The affected lots are lot #N02167A (bag) and lot #N02167 (blister), both expiring in July 2026.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals Levothyroxine 125 mcg recalled for subpotency
Major Pharmaceuticals is recalling specific lots of Levothyroxine Sodium 125 mcg tablets because they may contain less active ingredient than labeled. Levothyroxine is a thyroid replacement medication, and tablets that are weaker than expected could result in inadequate thyroid hormone levels.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals Levothyroxine recalled for subpotency
Major Pharmaceuticals issued a recall of Levothyroxine Sodium 75 mcg tablets because some batches do not contain the full labeled amount of active ingredient. This means the medication may not work as intended for treating thyroid conditions. The affected batches have expiration dates of July 2026 and December 2026.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals levothyroxine tablets recalled for low potency
Major Pharmaceuticals levothyroxine sodium 50 mcg tablets in certain lots contain less active ingredient than labeled, meaning they may not work as intended. This affects specific lot numbers expiring in October 2026 that were distributed nationwide.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals levothyroxine recalled for reduced potency
Major Pharmaceuticals levothyroxine sodium 25 mcg tablets in certain lots do not contain the full labeled amount of active ingredient. This means the medication may not work as intended to treat thyroid conditions. The affected lots (N02212A, N02212B, and blister lot N02212, all expiring 07/2026) were distributed nationwide.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals levothyroxine tablets recalled for subpotency
Major Pharmaceuticals is recalling one lot of levothyroxine sodium 150 mcg tablets because they do not contain the full stated dose of active ingredient. Patients taking this medication need the correct dose to manage their thyroid condition properly.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals levothyroxine tablets recalled for subpotency
Major Pharmaceuticals is recalling one lot of Levothyroxine Sodium Tablets, USP 125 mcg due to subpotency—meaning the tablets contain less active ingredient than expected. This affects lot #N02266 with an expiration date of 11/2026. The affected tablets were distributed nationwide.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals Levothyroxine 112 mcg recalled for subpotency
Major Pharmaceuticals issued a recall of Levothyroxine Sodium 112 mcg tablets (Lot #N02203, expiring 09/2026) because the medication is subpotent—meaning it contains less active ingredient than labeled. Patients taking this lot may not receive the full intended dose of this thyroid replacement medication.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals Levothyroxine Sodium Tablets recalled for subpotency
Major Pharmaceuticals issued a recall of Levothyroxine Sodium Tablets, USP, 88 mcg (Lot #N02310, expiration 01/2027) because the tablets may contain less active ingredient than labeled. This means patients taking this medication may not receive the full intended dose of thyroid hormone.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals levothyroxine tablets recalled for subpotency
Major Pharmaceuticals is recalling certain lots of Levothyroxine Sodium Tablets, USP, 75 mcg because they may contain less active ingredient than labeled. Patients taking affected tablets may not receive the full intended dose of this thyroid hormone medication.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals levothyroxine tablets recalled for reduced potency
Major Pharmaceuticals is recalling levothyroxine sodium 50 mcg tablets (lot N02200, expiration 10/2026) because they do not contain the full labeled dose. Levothyroxine is a thyroid hormone replacement medication, and a subpotent tablet may not provide the intended therapeutic effect for patients who depend on consistent dosing.
- 2026-07-29FDA-DrugClass IIMajor Pharmaceuticals levothyroxine tablets recalled for subpotency
Major Pharmaceuticals is recalling one lot of Levothyroxine Sodium Tablets, USP, 25 mcg due to subpotency — meaning the tablets contain less active ingredient than labeled. This affects Lot N02212 with an expiration date of 07/2026. Patients taking subpotent levothyroxine may not receive the full intended dose of this thyroid hormone replacement medication.
Get notified about new Major Pharmaceuticals recalls
Free weekly digest. We email when a new federal recall affects Major Pharmaceuticals or anything else in your household.
Get the Sunday Brief